Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) has shown positive clinical outcomes in somatostatin receptor (SSTR) overexpressing positive well-differentiated neuroendocrine tumors in combination with somatostatin analogue therapy. A noted decreased progression-free survivability in the use of PRRT has been noted in larger lesions (>3cm).
Conference:
Presenting Author: Azarraga C
Authors: Azarraga C, Leogardo D, Bandong I, Bautista-Peñalosa P,
Keywords: neuroendocrine, PRRT, intra-arterial, bulky,
Introduction: Refractory carcinoid syndrome (RCSy) could lead to severe complications.
Conference:
Presenting Author: Tőke J
Authors: Tőke J, Kövesdi A, Szolnoky J, Huszty G, Piros L,
Keywords: refractory carcinoid syndrome, liver transplantation, ileum neuroendocrine tumor,
Introduction: Treatment with 177Lu is standard of care for wdNET with high somatostatin receptor expression. Patterns of response could differ between hepatic (hep) and extrahepatic (ehep) met.
Conference:
Presenting Author:
Authors: Sánchez Gómez L, Guillén Sentís P, Ruffinelli J, Torrent F, Vercher Conejero J,
Keywords: 177lu-dotatate, well-differentiated neuroendocrine tumor, tumor growth rate,
#3950 Liver debulking surgery affect the treatment efficacy of SSAs
Introduction: Since the results of the previous study, liver metastasis tumor burden affect the treatment effect of somatostatin analogues (SSAs).
Conference:
Presenting Author: Liang Y
Authors: Liang Y, Zhou J, Chen J,
Keywords: Liver metastasis, debulking surgery, SSAs,
#3890 Intracardiac metastasis in well-differentiated ileal neuroendocrine tumor
Introduction: About 60% of well-differentiated neuroendocrine tumors are diagnosed with metastatic disease, above all with liver involvement. The incidence of myocardial metastasis in patients with metastatic neuroendocrine tumor is less than 4%. These are mostly asymptomatic metastasis, so the diagnosis is often incidental.
Conference:
Presenting Author: Della Torre S
Authors: Della Torre S, Smiroldo V, Cozzi C, Galeassi A, Di Bella S,
Keywords: cardiac metastasis, neuroendocrine tumor,